Telix Pharmaceuticals

Clinical Trial · NCT07197580

A Phase 3, Randomized, Multi-Center, Open-Label Study to Compare 177Lu-TLX250 (Lutetium (177Lu) Girentuximab Tetraxetan) With the Investigator's Choice of a Single Agent Therapy in Participants With Carbonic Anhydrase 9 (CAIX) Expressing, Advanced Relapsed or Recurrent Clear Cell Renal Cell Carcinoma (ccRCC)

Overview

Multicenter Phase 3 study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC). Part 1 will evaluate two dosing regimens to determine the recommended Phase 3 dose (RP3D). Part 2 will compare 177Lu-TLX250 with investigator's choice of monotherapy

Phase

Phase 3

Contacts

Prson Gautam, PhD

prson.gautam@telixpharma.com

19196508158

ClinicalTrials.gov

NCT07197580

Drug / Compound

177Lu-TLX250

Isotope(s):
Target(s):
  • CAIX

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…